11 December 2007
Pronova BioPharma has selected NNE Pharmaplan to establish their new pharmaceutical production facility in Kalundborg, Denmark. Under the contract, NNE Pharmaplan will be responsible of Engineering, Procurement, Construction Management and Validation (EPCMV). In addition the contract includes automation integration. The new facility will be approved according to Good Manufacturing Practice (GMP).
Pronova BioPharma is a global leader in the research, development and manufacturing of marine-originated, omega-3 fatty acids derived pharmaceutical products for prevention of cardiovascular diseases. The new facility in Kalundborg is expected to double Pronova BioPharma's current production capacity of the active pharmaceutical ingredient used in the company’s lead product, marketed as Omacor in Europe and Lovaza in the United States.
The contract will be signed tomorrow on Wednesday 12 December at an official ceremony in Kalundborg (see details below). The project is expected to last for 18 months and will at peak involve approximately 180 engineers.
“This is a great achievement for NNE Pharmaplan. It proves our unique position in the life science industry and provides a compelling offer to pharma and biotech companies searching for the combination of global reach, local presence and years of dedicated experience within this field,” said Hans Ole Voigt, NNE Pharmaplan CEO.
Pronova BioPharma plans to invest between NOK 1.45 and 1.70 billion in the new facility, which isexpected to be operational and approved by the relevant regulatory authorities by the first half of 2010.
Tomas Settevik, CEO at Pronova BioPharma said: “NNE Pharmaplan’s well proven fast-track capabilities and their plan for having a fully operational facility ready in Kalundborg four to six months earlier than any other location we have looked at was a decisive factor for choosing NNE Pharmaplan as our cooperation partner. It enables us to continue our fast growth and ensures that we are well positioned to meet the global market’s accelerating demand for our products."
NNE Pharmaplan has a solid track record for establishing life science production facilities in a very short time without compromising safety or quality requirements of often complex manufacturing processes, and in full compliance with GMP regulations required for the production of pharmaceutical products.
“It is our mission to enable our clients to bring their products to markets in a fast, reliable and innovative way. Seven years ago we decided to be the fastest in the world to build new facilities for production of medicines. Five years later we reached that target. Today it makes NNE Pharmaplan a very attractive choice for medicine companies worldwide aiming to go to the market in a short time,” said Hans Ole Voigt.
Press briefing
Representatives from NNE Pharmaplan and Pronova BioPharma will sign the contract at a short official ceremony on Wednesday 12 December 2007. The ceremony is open for the press and will take place on Juelsmindevej 5 in Kalundborg, Denmark, at 10.30–11.00 (local time).
For further information
Hans Ole Voigt, CEO
T: +45 3079 7441
Peter Lau-Jensen, VP Sales & Sites, Denmark
T: +45 3075 5432
Kasper Riis, Communications Manager
T: +45 3079 8316
About NNE Pharmaplan
NNE Pharmaplan is the world's leading engineering and consultancy company that focuses exclusively on the pharmaceutical and biotechnological industries.
NNE Pharmaplan covers the entire pharmaceutical supply chain from product development to manufacturing with knowledge, expertise and well-proven solutions founded on more than 80 years of experience in the life science industry.
Headquartered in Copenhagen, Denmark, NNE Pharmaplan employs more than 1500 people at over 20 locations around the world and offers global reach and local knowledge along with an all-encompassing list of services.
Click here to download a PDF-version